These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21299475)

  • 1. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
    Woodruff PG; Albert RK; Bailey WC; Casaburi R; Connett JE; Cooper JA; Criner GJ; Curtis JL; Dransfield MT; Han MK; Harnden SM; Kim V; Marchetti N; Martinez FJ; McEvoy CE; Niewoehner DE; Reilly JJ; Rice K; Scanlon PD; Scharf SM; Sciurba FC; Washko GR; Lazarus SC;
    COPD; 2011 Feb; 8(1):21-9. PubMed ID: 21299475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
    Grissom CK; Richer LD; Elstad MR
    Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E; Cohn J; Dubé L; Drazen JM
    JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
    J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
    DuBuske LM; Grossman J; Dubé LM; Swanson LJ; Lancaster JF
    Am J Manag Care; 1997 Apr; 3(4):633-40. PubMed ID: 10169531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
    Schwartz HJ; Petty T; Dubé LM; Swanson LJ; Lancaster JF
    Arch Intern Med; 1998 Jan; 158(2):141-8. PubMed ID: 9448552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
    Hackshaw KV; Shi Y; Brandwein SR; Jones K; Westcott JY
    J Rheumatol; 1995 Mar; 22(3):462-8. PubMed ID: 7783062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
    Berger W; De Chandt MT; Cairns CB
    Int J Clin Pract; 2007 Apr; 61(4):663-76. PubMed ID: 17394438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.
    Kane GC; Pollice M; Kim CJ; Cohn J; Dworski RT; Murray JJ; Sheller JR; Fish JE; Peters SP
    J Allergy Clin Immunol; 1996 Feb; 97(2):646-54. PubMed ID: 8621850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
    Hawkey CJ; Dube LM; Rountree LV; Linnen PJ; Lancaster JF
    Gastroenterology; 1997 Mar; 112(3):718-24. PubMed ID: 9041232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.
    Tardif JC; L'allier PL; Ibrahim R; Grégoire JC; Nozza A; Cossette M; Kouz S; Lavoie MA; Paquin J; Brotz TM; Taub R; Pressacco J
    Circ Cardiovasc Imaging; 2010 May; 3(3):298-307. PubMed ID: 20190281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
    Mohebati A; Milne GL; Zhou XK; Duffield-Lillico AJ; Boyle JO; Knutson A; Bosworth BP; Kingsley PJ; Marnett LJ; Brown PH; Akpa EG; Szabo E; Dannenberg AJ
    Cancer Prev Res (Phila); 2013 Jul; 6(7):646-55. PubMed ID: 23682075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
    Nelson H; Kemp J; Berger W; Corren J; Casale T; Dube L; Walton-Bowen K; LaVallee N; Stepanians M
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):178-84. PubMed ID: 17718106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
    Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.
    Wenzel S; Busse W; Calhoun W; Panettieri R; Peters-Golden M; Dube L; Walton-Bowen K; Russell H; Harris J
    J Asthma; 2007 May; 44(4):305-10. PubMed ID: 17530530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.